Form 4 for CRBP Corbus Pharmaceuticals Holdings, Inc.
Accepted 2024-06-18 00:00:00 ET · period of report 2024-06-14 · accession 0000950170-24-075075 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2024-06-18 | 2024-06-14+ | CRBP | Moran Sean F. | CFO | S - Sale+OE | $47.87 | -18.0K | 48.6K | -27% | -$863.8K |
| DMT | 2024-06-18 | 2024-06-14+ | CRBP | Moran Sean F. | CFO | M - OptEx | $12.96 | +18.0K | 56.4K | +47% | +$233.8K |
| DMT | 2024-06-18 | 2024-06-14+ | CRBP | Moran Sean F. | CFO | M - OptEx | $0.00 | -18.0K | 11.2K | -62% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock, par value $0.0001 per share | 2024-06-17 | S | D | 6,730 | $46.77 | 48,605 | D | — | — | (F4) The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.88 to $49.47 per share, inclusive. The reporting person undertakes to provide to Corbus Pharmaceuticals Holdings, Inc., any security holder of Corbus Pharmaceuticals Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. (F1) This amount includes 40,176 restricted stock units ("RSUs"), which vest 25% on each of the first, second, third and fourth anniversary beginning on February 12, 2025. |
| 2 | Common | Common Stock, par value $0.0001 per share | 2024-06-18 | M | A | 1,958 | $30.00 | 50,563 | D | — | — | (F1) This amount includes 40,176 restricted stock units ("RSUs"), which vest 25% on each of the first, second, third and fourth anniversary beginning on February 12, 2025. |
| 3 | Common | Common Stock, par value $0.0001 per share | 2024-06-18 | S | D | 1,958 | $42.12 | 48,605 | D | — | — | (F5) The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.10 to $43.59 per share, inclusive. The reporting person undertakes to provide to Corbus Pharmaceuticals Holdings, Inc., any security holder of Corbus Pharmaceuticals Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. (F1) This amount includes 40,176 restricted stock units ("RSUs"), which vest 25% on each of the first, second, third and fourth anniversary beginning on February 12, 2025. |
| 4 | Common | Common Stock, par value $0.0001 per share | 2024-06-17 | M | A | 6,730 | $14.10 | 55,335 | D | — | — | (F1) This amount includes 40,176 restricted stock units ("RSUs"), which vest 25% on each of the first, second, third and fourth anniversary beginning on February 12, 2025. |
| 5 | Common | Common Stock, par value $0.0001 per share | 2024-06-14 | S | D | 7,788 | $49.87 | 48,605 | D | — | — | (F3) The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.26 to $52.525 per share, inclusive. The reporting person undertakes to provide to Corbus Pharmaceuticals Holdings, Inc., any security holder of Corbus Pharmaceuticals Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. (F1) This amount includes 40,176 restricted stock units ("RSUs"), which vest 25% on each of the first, second, third and fourth anniversary beginning on February 12, 2025. |
| 6 | Common | Common Stock, par value $0.0001 per share | 2024-06-14 | S | D | 1,567 | $49.87 | 48,605 | D | — | — | (F3) The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.26 to $52.525 per share, inclusive. The reporting person undertakes to provide to Corbus Pharmaceuticals Holdings, Inc., any security holder of Corbus Pharmaceuticals Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. (F1) This amount includes 40,176 restricted stock units ("RSUs"), which vest 25% on each of the first, second, third and fourth anniversary beginning on February 12, 2025. |
| 7 | Common | Common Stock, par value $0.0001 per share | 2024-06-14 | M | A | 1,567 | $30.00 | 50,172 | D | — | — | (F1) This amount includes 40,176 restricted stock units ("RSUs"), which vest 25% on each of the first, second, third and fourth anniversary beginning on February 12, 2025. |
| 8 | Common | Common Stock, par value $0.0001 per share | 2024-06-14 | M | A | 7,788 | $4.26 | 56,393 | D | — | — | (F1) This amount includes 40,176 restricted stock units ("RSUs"), which vest 25% on each of the first, second, third and fourth anniversary beginning on February 12, 2025. |
| 9 | Derivative | Options to purchase common stock | 2024-06-18 | M | D | 1,958 | $0.00 | 0 | D | $30.00 · — to 2024-10-22 | 1,958 Common Stock | (F6) The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan and is fully vested. |
| 10 | Derivative | Options to purchase common stock | 2024-06-14 | M | D | 7,788 | $0.00 | 23,367 | D | $4.26 · 2024-02-13 to 2033-02-13 | 7,788 Common Stock | (F7) The annual option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vested on February 13, 2024, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on March 13, 2024. |
| 11 | Derivative | Options to purchase common stock | 2024-06-14 | M | D | 1,567 | $0.00 | 1,958 | D | $30.00 · — to 2024-10-22 | 1,567 Common Stock | (F6) The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan and is fully vested. |
| 12 | Derivative | Options to purchase common stock | 2024-06-17 | M | D | 6,730 | $0.00 | 11,217 | D | $14.10 · 2023-02-01 to 2032-02-01 | 6,730 Common Stock | (F8) The annual option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vested on February 1, 2023, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on March 2, 2023. |